THE CLINICAL AND ECONOMIC IMPACT OF DOLUTEGRAVIR-BASED FIRST-LINE ART IN INDIA
Dolutegravir (DTG)-based antiretroviral therapy (ART) has proven superior or non-inferior to other regimens and is recommended first-line treatment in the US. Efavirenz (EFV)-based regimens remain the standard of care (SOC) in India and other resource-limited settings, where DTG is not yet available. Anticipating generic DTG availability, we examined the clinical outcomes, cost-effectiveness, and budgetary impact…